MarketPulse

autoimmune disease

14 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

LBL-047 Advances to Clinical Testing for Autoimmune Diseases as Dianthus Raises $719M

Nanjing Leads Biolabs and Dianthus Therapeutics advance LBL-047, a bifunctional fusion protein, into Phase 1 trials for three autoimmune conditions with $719M in funding.
DNTHclinical developmentautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyverna's Miv-cel Shows Durable Benefits in Stiff Person Syndrome Trial

Kyverna's miv-cel shows statistically significant benefits across all endpoints in stiff person syndrome trial, with 81% achieving meaningful walking speed improvement.
KYTXclinical trialautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Myasthenia Gravis Market Poised for Transformation With 8 Late-Stage Drug Candidates

Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.
NVSAZNREGNMKKGYROIV+3clinical trialsautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Priovant Advances Rare Disease Pipeline with Fourth Brepocitinib Indication

Priovant initiates Phase 2b/3 trial for brepocitinib in lichen planopilaris, marking fourth indication; dermatomyositis FDA decision expected Q3 2026.
ROIVFDA approvalrare disease
BenzingaBenzinga··Bamboo Works

Keymed's $320M Windfall: Chinese Biotech Scores Major Exit via Gilead Acquisition

Keymed Biosciences receives up to $320M from Gilead's acquisition of its immunotherapy spinoff Ouro Medicines, marking a landmark exit for Chinese biotech.
AZNGILDacquisitionautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

SLE Drug Race Heats Up: 120+ Pharma Giants Develop 140+ Pipeline Therapies

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.
JNJABBVNVSRHHBYAZN+3FDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Priovant Therapeutics / Roivant Sciences

Priovant's Brepocitinib Clears Phase 3 Trial for Rare Muscle Disease, Eyes 2026 FDA Approval

Priovant's brepocitinib met Phase 3 endpoints for dermatomyositis treatment, earning FDA Priority Review with Q3 2026 decision expected.
ROIVclinical trial resultsautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sitryx to Showcase Autoimmune Pipeline at Four Major Biopharma Conferences in April

Clinical-stage biotech Sitryx Therapeutics will present at four investor conferences in April 2026, highlighting its oral autoimmune and inflammatory disease therapies.
LLYGSKoral therapyinvestor conference
BenzingaBenzinga··Vandana Singh

Gilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.
GILDACLXGLPGacquisitionorphan drug designation
BenzingaBenzinga··Globe Newswire

SAB Biotherapeutics Raises $85M to Advance Type 1 Diabetes Treatment

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.
SABSSABSWclinical trialpublic offering
BenzingaBenzinga··Vandana Singh

Novartis Expands Cosentyx Reach Into Pediatric Dermatology With FDA Approval

Novartis wins FDA approval for Cosentyx in pediatric hidradenitis suppurativa patients aged 12+, marking the drug's fourth pediatric indication and expanding its dermatology portfolio.
NVSFDA approvalautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus to Unveil Phase 3 CIDP Trial Data as Claseprubart Nears Potential Breakthrough

Dianthus Therapeutics will present interim responder analysis from Phase 3 CAPTIVATE trial of claseprubart for CIDP treatment on March 9, 2026.
DNTHclinical-stage biotechPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx's VYVGART Meets Primary Endpoint in Ocular Myasthenia Gravis Trial

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.
ARGXFDA approvalPhase 3 trial